Patrícia Marques-Alves
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Patrícia Marques-Alves has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
Lino Gonçalves
Pacing & Electrophysiology Unit, Cardiology Department Coimbra's Hospital and University Center Coimbra Portugal
14 shared publications- Rui Baptista
Cardiology Department, Unidade Local de Saúde de Entre o Douro e Vouga , Santa Maria da Feira
6 shared publications Rui Martins
Departamento de Cardiologia Centro Hospitalar e Universitário de Coimbra Coimbra Portugal Departamento de Cardiologia , Centro Hospitalar e Universitário de Coimbra , Coimbra – Portugal
5 shared publicationsAna Vera Marinho
Department of Cardiology Centro Hospitalar e Universitário de Coimbra Coimbra Portugal
4 shared publicationsFátima Franco
Department of Cardiology Centro Hospitalar e Universitário de Coimbra Coimbra Portugal
3 shared publicationsGraça Castro
Departamento de Cardiologia Centro Hospitalar e Universitário de Coimbra Coimbra Portugal Departamento de Cardiologia , Centro Hospitalar e Universitário de Coimbra , Coimbra – Portugal
3 shared publications
Latest Publications
- 6 October 2026
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 37 (11) , 2751-2759
Enhancing Persistent Atrial Fibrillation Ablation: The Added Value of Vein of Marshall Ethanol Infusion in a Tailored Strategy
Background: Outcomes following catheter ablation for persistent atrial fibrillation (AF) remain suboptimal. Low‐voltage areas (LVA), as a surrogate for atrial fibrosis, have been targeted due to their association with arrhythmia recurrence. Ethanol infusion in the vein of Marshall (VoM) has emerged as an adjunctive strategy that may enhance ablation efficacy. We evaluated the effectiveness of a tailored ablation strategy guided by the presence of LVA and incorporating VoM ethanol infusion in patients with persistent AF. Methods: This prospective, single‐center study included patients referred for catheter ablation for persistent AF ablation between August 2022 and August 2024. Patients underwent a tailored ablation strategy guided by the presence of LVA. Procedural endpoints and 1‐year outcomes were assessed and compared with those of a propensity score‐matched cohort undergoing pulmonary vein isolation (PVI) alone. Results: A total of 118 patients (71% male, mean age of 62 ± 10years) were included in our study: 59 in the tailored approach group and 59 propensity score‐matched controls. In the tailored group, VoM ethanol infusion was performed in 60% of patients, while ablation beyond pulmonary veins was not performed in 14% of patients due to LVA absence. Bidirectional block was achieved in all ablation lines except in two patients. At 1‐year follow‐up, 22% of patients had atrial arrhythmia recurrence. The risk of recurrence was significantly lower in the tailored approach group (13.5% vs. 30.5%, p = 0.02). A tailored approach was independently associated with freedom from atrial arrhythmia recurrence (HR 0.41 [0.17–0.94], p = 0.04). No significant differences in adverse events were observed between groups. Conclusions: In patients with persistent AF, a tailored ablation guided by LVAs was associated with significantly lower arrhythmia recurrence at 1‐year compared with PVI alone.
- 6 October 2026
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 37 (11) , 2751-2759
Enhancing Persistent Atrial Fibrillation Ablation: The Added Value of Vein of Marshall Ethanol Infusion in a Tailored Strategy
Background: Outcomes following catheter ablation for persistent atrial fibrillation (AF) remain suboptimal. Low‐voltage areas (LVA), as a surrogate for atrial fibrosis, have been targeted due to their association with arrhythmia recurrence. Ethanol infusion in the vein of Marshall (VoM) has emerged as an adjunctive strategy that may enhance ablation efficacy. We evaluated the effectiveness of a tailored ablation strategy guided by the presence of LVA and incorporating VoM ethanol infusion in patients with persistent AF. Methods: This prospective, single‐center study included patients referred for catheter ablation for persistent AF ablation between August 2022 and August 2024. Patients underwent a tailored ablation strategy guided by the presence of LVA. Procedural endpoints and 1‐year outcomes were assessed and compared with those of a propensity score‐matched cohort undergoing pulmonary vein isolation (PVI) alone. Results: A total of 118 patients (71% male, mean age of 62 ± 10years) were included in our study: 59 in the tailored approach group and 59 propensity score‐matched controls. In the tailored group, VoM ethanol infusion was performed in 60% of patients, while ablation beyond pulmonary veins was not performed in 14% of patients due to LVA absence. Bidirectional block was achieved in all ablation lines except in two patients. At 1‐year follow‐up, 22% of patients had atrial arrhythmia recurrence. The risk of recurrence was significantly lower in the tailored approach group (13.5% vs. 30.5%, p = 0.02). A tailored approach was independently associated with freedom from atrial arrhythmia recurrence (HR 0.41 [0.17–0.94], p = 0.04). No significant differences in adverse events were observed between groups. Conclusions: In patients with persistent AF, a tailored ablation guided by LVAs was associated with significantly lower arrhythmia recurrence at 1‐year compared with PVI alone.
- Open Access
- 1 December 2025
- Published by KEAI Publishing in Meta-Radiology
- Vol. 3 (4)
2-[18F]FDG PET/CT identifies metabolic activity linked to myocardial deformation in hypertrophic cardiomyopathy
- 1 December 2025
- Published by KEAI Publishing in Meta-Radiology
- Vol. 3 (4)
Open Access2-[18F]FDG PET/CT identifies metabolic activity linked to myocardial deformation in hypertrophic cardiomyopathy
- Open Access
- 21 November 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 41298
2-[18F]FDG PET identifies metabolic substrates of sudden cardiac death in hypertrophic cardiomyopathy
Risk stratification for sudden cardiac death (SCD) in hypertrophic cardiomyopathy (HCM) remains challenging. Enhanced imaging techniques could improve prognostic accuracy. This study investigates myocardial resting perfusion and metabolism using [13N]-NH3 and 2-[18F]FDG PET/CT and their correlation with HCM SCD risk scores. Thirty non-obstructive HCM patients (mean age 54 years, 57% male) with a mean SCD risk score of 3.7 ± 2.5% were evaluated. Myocardial 2-[18F]FDG metabolism and rest [13N]-NH3 perfusion PET/CT were analyzed. Hypermetabolism (2-[18F]FDG uptake with normal perfusion) occurred in 53% of cases (mean extension 11.8 ± 17.2%), while fibrosis (reduced perfusion without 2-[18F]FDG uptake) averaged 10.3 ± 10.2%. Mean rest myocardial blood flow (MBF) was 0.75 ± 0.21 ml/min/g, increasing with hypermetabolism extension (0.83 ± 0.32 ml/min/g for ≥ 20%, p = 0.019) but decreasing with SCD scores ≥ 6% (0.58 ± 0.05 ml/min/g, p = 0.034). Hypermetabolism correlated moderately with SCD risk scores (rho = 0.38, p = 0.036), with hypermetabolism peaking at intermediate risk (23.5 ± 27.1%) before declining. Fibrosis extension consistently increased with SCD risk (rho = 0.38, p = 0.039). In conclusion, our findings identify important correlations between myocardial hypermetabolism and fibrosis and SCD risk in HCM. Hypermetabolism peaks in intermediate-risk patients, reflecting earlier disease stages, while fibrosis increases with higher SCD risk, signaling disease progression and structural damage.
- 21 November 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 41298
Open Access2-[18F]FDG PET identifies metabolic substrates of sudden cardiac death in hypertrophic cardiomyopathy
Risk stratification for sudden cardiac death (SCD) in hypertrophic cardiomyopathy (HCM) remains challenging. Enhanced imaging techniques could improve prognostic accuracy. This study investigates myocardial resting perfusion and metabolism using [13N]-NH3 and 2-[18F]FDG PET/CT and their correlation with HCM SCD risk scores. Thirty non-obstructive HCM patients (mean age 54 years, 57% male) with a mean SCD risk score of 3.7 ± 2.5% were evaluated. Myocardial 2-[18F]FDG metabolism and rest [13N]-NH3 perfusion PET/CT were analyzed. Hypermetabolism (2-[18F]FDG uptake with normal perfusion) occurred in 53% of cases (mean extension 11.8 ± 17.2%), while fibrosis (reduced perfusion without 2-[18F]FDG uptake) averaged 10.3 ± 10.2%. Mean rest myocardial blood flow (MBF) was 0.75 ± 0.21 ml/min/g, increasing with hypermetabolism extension (0.83 ± 0.32 ml/min/g for ≥ 20%, p = 0.019) but decreasing with SCD scores ≥ 6% (0.58 ± 0.05 ml/min/g, p = 0.034). Hypermetabolism correlated moderately with SCD risk scores (rho = 0.38, p = 0.036), with hypermetabolism peaking at intermediate risk (23.5 ± 27.1%) before declining. Fibrosis extension consistently increased with SCD risk (rho = 0.38, p = 0.039). In conclusion, our findings identify important correlations between myocardial hypermetabolism and fibrosis and SCD risk in HCM. Hypermetabolism peaks in intermediate-risk patients, reflecting earlier disease stages, while fibrosis increases with higher SCD risk, signaling disease progression and structural damage.
- Open Access
- 28 February 2025
- Published by Springer Nature in EJNMMI Research
- Vol. 15 (1) , 1-10
Molecular imaging in hypertrophic cardiomyopathy: an exploratory study with 2-[18F]FDG and [13N]NH3
Hypertrophic Cardiomyopathy (HCM), a genetic disorder with diverse phenotypes, is associated with risks of heart failure and sudden cardiac death. While the condition involves multiple pathological pathways, including myocardial inflammation, increased workload, myocyte disarray, apoptosis, and fibrosis, the role of molecular imaging via PET-CT remains unexplored in this context. This study aimed to investigate the relationship between myocardial metabolism and perfusion using PET-CT in patients with non-obstructive HCM (NOHCM). Myocardial perfusion and metabolism were assessed using PET-CT with [13N]NH3 and 2-[18F]FDG uptake, respectively, in 30 NOHCM patients. Baseline measurements included maximal myocardial wall thickness (MMWT), left atrial volume (LAV), NT-proBNP levels, and the sudden cardiac death (SCD) risk score. Increased 2-[18F]FDG uptake (Target to Background Ratio – TBR ≥ 1.1) was detected in 53% of patients, with an average TBR of 1.4 ± 0.5. The inflammatory pattern involved 11.8 ± 17.2% of the left ventricle (LV) and correlated with MMWT (rho = 0.49, p = 0.009), LAV (rho = 0.39, p = 0.04), and NT-proBNP levels (rho = 0.63, p = 0.003). The maximum TBR within the LV correlated with MMWT (rho = 0.53, p = 0.004), NT-proBNP (rho = 0.70,p = 0.0008), and the SCD risk score (rho = 0.38,p = 0.04). Additionally, the fibrotic (scar) pattern, involving 10.3 ± 10.2% of the LV, correlated with the SCD score (rho = 0.38,p = 0.04). In patients with NOHCM, PET-CT imaging provides valuable insights into myocardial metabolism and fibrosis, which are closely associated with myocardial hypertrophy, left ventricular dysfunction, and the risk of sudden cardiac death.
- 28 February 2025
- Published by Springer Nature in EJNMMI Research
- Vol. 15 (1) , 1-10
Open AccessMolecular imaging in hypertrophic cardiomyopathy: an exploratory study with 2-[18F]FDG and [13N]NH3
Hypertrophic Cardiomyopathy (HCM), a genetic disorder with diverse phenotypes, is associated with risks of heart failure and sudden cardiac death. While the condition involves multiple pathological pathways, including myocardial inflammation, increased workload, myocyte disarray, apoptosis, and fibrosis, the role of molecular imaging via PET-CT remains unexplored in this context. This study aimed to investigate the relationship between myocardial metabolism and perfusion using PET-CT in patients with non-obstructive HCM (NOHCM). Myocardial perfusion and metabolism were assessed using PET-CT with [13N]NH3 and 2-[18F]FDG uptake, respectively, in 30 NOHCM patients. Baseline measurements included maximal myocardial wall thickness (MMWT), left atrial volume (LAV), NT-proBNP levels, and the sudden cardiac death (SCD) risk score. Increased 2-[18F]FDG uptake (Target to Background Ratio – TBR ≥ 1.1) was detected in 53% of patients, with an average TBR of 1.4 ± 0.5. The inflammatory pattern involved 11.8 ± 17.2% of the left ventricle (LV) and correlated with MMWT (rho = 0.49, p = 0.009), LAV (rho = 0.39, p = 0.04), and NT-proBNP levels (rho = 0.63, p = 0.003). The maximum TBR within the LV correlated with MMWT (rho = 0.53, p = 0.004), NT-proBNP (rho = 0.70,p = 0.0008), and the SCD risk score (rho = 0.38,p = 0.04). Additionally, the fibrotic (scar) pattern, involving 10.3 ± 10.2% of the LV, correlated with the SCD score (rho = 0.38,p = 0.04). In patients with NOHCM, PET-CT imaging provides valuable insights into myocardial metabolism and fibrosis, which are closely associated with myocardial hypertrophy, left ventricular dysfunction, and the risk of sudden cardiac death.
- Open Access
- 8 January 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (2) , 133
PET-CT Imaging in Hypertrophic Cardiomyopathy: A Narrative Review on Risk Stratification and Prognosis
Hypertrophic cardiomyopathy (HCM) is a heterogeneous cardiac disease and one of its major challenges is the limited accuracy in stratifying the risk of sudden cardiac death (SCD). Positron emission tomography (PET), through the evaluation of myocardial blood flow (MBF) and metabolism using fluorodeoxyglucose (FDG) uptake, can reveal microvascular dysfunction, ischemia, and increased metabolic demands in the hypertrophied myocardium. These abnormalities are linked to several factors influencing disease progression, including arrhythmia development, ventricular dilation, and myocardial fibrosis. Fibroblast activation can also be evaluated using PET imaging, providing further insights into early-stage myocardial fibrosis. Conflicting findings underscore the need for further research into PET’s role in risk stratification for HCM. If PET can establish a connection between parameters such as abnormal MBF or increased FDG uptake and SCD risk, it could enhance predictive accuracy. Additionally, PET holds significant potential for monitoring therapeutic outcomes. The aim of this review is to provide a comprehensive overview of the most significant data on disease progression, risk stratification, and prognosis in patients with HCM using cardiac PET-CT imaging.
- 8 January 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (2) , 133
Open AccessPET-CT Imaging in Hypertrophic Cardiomyopathy: A Narrative Review on Risk Stratification and Prognosis
Hypertrophic cardiomyopathy (HCM) is a heterogeneous cardiac disease and one of its major challenges is the limited accuracy in stratifying the risk of sudden cardiac death (SCD). Positron emission tomography (PET), through the evaluation of myocardial blood flow (MBF) and metabolism using fluorodeoxyglucose (FDG) uptake, can reveal microvascular dysfunction, ischemia, and increased metabolic demands in the hypertrophied myocardium. These abnormalities are linked to several factors influencing disease progression, including arrhythmia development, ventricular dilation, and myocardial fibrosis. Fibroblast activation can also be evaluated using PET imaging, providing further insights into early-stage myocardial fibrosis. Conflicting findings underscore the need for further research into PET’s role in risk stratification for HCM. If PET can establish a connection between parameters such as abnormal MBF or increased FDG uptake and SCD risk, it could enhance predictive accuracy. Additionally, PET holds significant potential for monitoring therapeutic outcomes. The aim of this review is to provide a comprehensive overview of the most significant data on disease progression, risk stratification, and prognosis in patients with HCM using cardiac PET-CT imaging.
- Open Access
- 29 March 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (7) , 6434
Incidence of Bloodstream Infection in Patients with Pulmonary Hypertension under Intravenous Epoprostenol or Iloprost—A Multicentre, Retrospective Study
Intravenous synthetic prostacyclin analogs (iPCAs), such as epoprostenol, treprostinil and iloprost have been widely used for the treatment of pulmonary arterial hypertension (PAH). Despite having good outcomes, continuous infusion of iPCAs has been associated with some adverse effects. Bloodstream infection (BSI) is one of the most severe complications, although poorly recognized, especially under iloprost administration, which few studies have addressed. This study aimed to compare the BSI incidence rates between intravenous iloprost and epoprostenol administration. Patients with pulmonary hypertension (PH) functional class III or IV receiving intravenous iloprost or epoprostenol through Hickman catheter, between 2004 and 2019, were retrospectively selected from two PH treatment centers. From a total of 36 patients (13 for iloprost and 23 for epoprostenol), 75% (n = 27) fulfilled the PAH criteria, mainly belonging to the idiopathic group. Overall BSI rate was 1.5/1000 days of treatment (3.38 and 0.09/1000 days for iloprost and epoprostenol, respectively). Patients receiving iloprost were at a higher risk of developing BSI than those receiving epoprostenol (HR: 12.5; 95% CI: 1.569–99.092). A higher mortality rate from BSI was also identified in the iloprost group (p = 0.04). Twenty-seven patients developed BSI, with 92% of them requiring hospitalization. A total of 29 agents were found, 10 Gram-positive (mainly Staphylococcus aureus; n = 5) and 19 Gram-negative (mainly Pseudomonas aeruginosa; n = 6) bacteria. Iloprost administration was linked to a significantly higher incidence of BSI, worse prognosis, and more BSI-related deaths than epoprostenol. BSI due to Gram-negative, commensal, low-virulence bacteria was also higher in the iloprost group. In short, physicians should be aware when prescribing iPCA to guarantee their patients’ safety and best medical care.
- 29 March 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (7) , 6434
Open AccessIncidence of Bloodstream Infection in Patients with Pulmonary Hypertension under Intravenous Epoprostenol or Iloprost—A Multicentre, Retrospective Study
Intravenous synthetic prostacyclin analogs (iPCAs), such as epoprostenol, treprostinil and iloprost have been widely used for the treatment of pulmonary arterial hypertension (PAH). Despite having good outcomes, continuous infusion of iPCAs has been associated with some adverse effects. Bloodstream infection (BSI) is one of the most severe complications, although poorly recognized, especially under iloprost administration, which few studies have addressed. This study aimed to compare the BSI incidence rates between intravenous iloprost and epoprostenol administration. Patients with pulmonary hypertension (PH) functional class III or IV receiving intravenous iloprost or epoprostenol through Hickman catheter, between 2004 and 2019, were retrospectively selected from two PH treatment centers. From a total of 36 patients (13 for iloprost and 23 for epoprostenol), 75% (n = 27) fulfilled the PAH criteria, mainly belonging to the idiopathic group. Overall BSI rate was 1.5/1000 days of treatment (3.38 and 0.09/1000 days for iloprost and epoprostenol, respectively). Patients receiving iloprost were at a higher risk of developing BSI than those receiving epoprostenol (HR: 12.5; 95% CI: 1.569–99.092). A higher mortality rate from BSI was also identified in the iloprost group (p = 0.04). Twenty-seven patients developed BSI, with 92% of them requiring hospitalization. A total of 29 agents were found, 10 Gram-positive (mainly Staphylococcus aureus; n = 5) and 19 Gram-negative (mainly Pseudomonas aeruginosa; n = 6) bacteria. Iloprost administration was linked to a significantly higher incidence of BSI, worse prognosis, and more BSI-related deaths than epoprostenol. BSI due to Gram-negative, commensal, low-virulence bacteria was also higher in the iloprost group. In short, physicians should be aware when prescribing iPCA to guarantee their patients’ safety and best medical care.
- Open Access
- 17 November 2021
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 118 (1) , 77-87
Mecânica Atrial na Cardiomiopatia Hipertrófica: Discriminando Hipertrofia de Fibrose Ventricular
Resumo Fundamento A cardiomiopatia hipertrófica (CMH) e a hipertrofia ventricular esquerda (HVE) secundária à hipertensão arterial sistêmica (HAS) podem estar associadas a anormalidades funcionais do átrio esquerdo (AE). Objetivos Caracterizar a mecânica do AE na CMH e na HAS e avaliar qualquer correlação com a extensão da fibrose ventricular esquerda medida por ressonância magnética cardíaca (RMC) em pacientes com CMH. Métodos A função longitudinal do AE derivada do ecocardiograma bidimensional com speckle tracking foi adquirida a partir de cortes apicais [...] Resumo Fundamento A cardiomiopatia hipertrófica (CMH) e a hipertrofia ventricular esquerda (HVE) secundária à hipertensão arterial sistêmica (HAS) podem estar associadas a anormalidades funcionais do átrio esquerdo (AE). Objetivos Caracterizar a mecânica do AE na CMH e na HAS e avaliar qualquer correlação com a extensão da fibrose ventricular esquerda medida por ressonância magnética cardíaca (RMC) em pacientes com CMH. Métodos A função longitudinal do AE derivada do ecocardiograma bidimensional com speckle tracking foi adquirida a partir de cortes apicais
- 17 November 2021
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 118 (1) , 77-87
Open AccessMecânica Atrial na Cardiomiopatia Hipertrófica: Discriminando Hipertrofia de Fibrose Ventricular
Resumo Fundamento A cardiomiopatia hipertrófica (CMH) e a hipertrofia ventricular esquerda (HVE) secundária à hipertensão arterial sistêmica (HAS) podem estar associadas a anormalidades funcionais do átrio esquerdo (AE). Objetivos Caracterizar a mecânica do AE na CMH e na HAS e avaliar qualquer correlação com a extensão da fibrose ventricular esquerda medida por ressonância magnética cardíaca (RMC) em pacientes com CMH. Métodos A função longitudinal do AE derivada do ecocardiograma bidimensional com speckle tracking foi adquirida a partir de cortes apicais [...] Resumo Fundamento A cardiomiopatia hipertrófica (CMH) e a hipertrofia ventricular esquerda (HVE) secundária à hipertensão arterial sistêmica (HAS) podem estar associadas a anormalidades funcionais do átrio esquerdo (AE). Objetivos Caracterizar a mecânica do AE na CMH e na HAS e avaliar qualquer correlação com a extensão da fibrose ventricular esquerda medida por ressonância magnética cardíaca (RMC) em pacientes com CMH. Métodos A função longitudinal do AE derivada do ecocardiograma bidimensional com speckle tracking foi adquirida a partir de cortes apicais
- 1 August 2021
- Published by Springer Nature in The International Journal of Cardiovascular Imaging
- Vol. 37 (8) , 2399-2408
Aortic strain in bicuspid aortic valve: an analysis
Bicuspid aortic valve (BAV) is monitored by transthoracic echocardiography and computed tomography (CT) angiography. However, it does not have any early marker of disease progression. This study evaluated speckle-tracking echocardiography (STE) aortic and left ventricular (LV) strain prognostic values, their discriminative power, and their correlation with the degree of valvular regurgitation. We conducted a retrospective analysis of a prospectively enrolled cohort of 45 diagnosed with BAV and 20 gender and age matched controls. We performed 2D-STE aortic and LV strain analysis of the selected population. The cohort was followed-up during a median period of 19.9 months (IQR 12.9-25.2), and outcomes (hospital admission for heart failure (HF), aortic valve replacement (AVR), and death) were determined. The mean patient age was 46.6 +/- 15.5 years and 80 % were male. LV indexed volumes and aortic diameter were higher in BAV patients. LV global longitudinal strain (GLS) was impaired (p < 0.001) and aortic GLS was significantly augmented (p = 0.027) in BAV patients. Aortic global circumferential strain (GCS) did not vary between groups. Aortic diameter was the best parameter related to BAV (AUC 0.92) and aortic GLS was best correlated with significant AR (AUC 0.76). AVR was the only outcome observed and its only predictor was indexed LV end-diastolic volume. BAV had impaired LV-GLS values. Aortic GLS was abnormally augmented in BAV patients, which might reflect higher aortic diameters that distorted strain calculations. STE aortic strain is related to AR but does not appear to be a reliable predictor of surgery in BAV patients, at 19 months.
- 1 August 2021
- Published by Springer Nature in The International Journal of Cardiovascular Imaging
- Vol. 37 (8) , 2399-2408
Aortic strain in bicuspid aortic valve: an analysis
Bicuspid aortic valve (BAV) is monitored by transthoracic echocardiography and computed tomography (CT) angiography. However, it does not have any early marker of disease progression. This study evaluated speckle-tracking echocardiography (STE) aortic and left ventricular (LV) strain prognostic values, their discriminative power, and their correlation with the degree of valvular regurgitation. We conducted a retrospective analysis of a prospectively enrolled cohort of 45 diagnosed with BAV and 20 gender and age matched controls. We performed 2D-STE aortic and LV strain analysis of the selected population. The cohort was followed-up during a median period of 19.9 months (IQR 12.9-25.2), and outcomes (hospital admission for heart failure (HF), aortic valve replacement (AVR), and death) were determined. The mean patient age was 46.6 +/- 15.5 years and 80 % were male. LV indexed volumes and aortic diameter were higher in BAV patients. LV global longitudinal strain (GLS) was impaired (p < 0.001) and aortic GLS was significantly augmented (p = 0.027) in BAV patients. Aortic global circumferential strain (GCS) did not vary between groups. Aortic diameter was the best parameter related to BAV (AUC 0.92) and aortic GLS was best correlated with significant AR (AUC 0.76). AVR was the only outcome observed and its only predictor was indexed LV end-diastolic volume. BAV had impaired LV-GLS values. Aortic GLS was abnormally augmented in BAV patients, which might reflect higher aortic diameters that distorted strain calculations. STE aortic strain is related to AR but does not appear to be a reliable predictor of surgery in BAV patients, at 19 months.
- 6 May 2021
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 116 (5) , 928-937
Valor Prognóstico de Níveis Elevados de Troponina I Isolados em Pacientes sem Síndrome Coronariana Aguda Admitidos no Serviço de Emergência
Resumo Fundamento: Embora a elevação não isquêmica da troponina seja frequentemente observada em pacientes admitidos no pronto-socorro (PS), não há consenso quanto ao seu manejo. Objetivos: Este estudo teve como objetivo caracterizar os pacientes admitidos no PS com elevação da troponina não-isquêmica e identificar potenciais preditores de mortalidade nessa população. Métodos: Este estudo observacional retrospectivo incluiu pacientes do PS com resultado positivo no teste da troponina entre junho e julho de 2015. Pacientes com diagnóstico clínico de síndrome coronariana aguda [...] Resumo Fundamento: Embora a elevação não isquêmica da troponina seja frequentemente observada em pacientes admitidos no pronto-socorro (PS), não há consenso quanto ao seu manejo. Objetivos: Este estudo teve como objetivo caracterizar os pacientes admitidos no PS com elevação da troponina não-isquêmica e identificar potenciais preditores de mortalidade nessa população. Métodos: Este estudo observacional retrospectivo incluiu pacientes do PS com resultado positivo no teste da troponina entre junho e julho de 2015. Pacientes com diagnóstico clínico de síndrome coronariana aguda
- 6 May 2021
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 116 (5) , 928-937
Valor Prognóstico de Níveis Elevados de Troponina I Isolados em Pacientes sem Síndrome Coronariana Aguda Admitidos no Serviço de Emergência
Resumo Fundamento: Embora a elevação não isquêmica da troponina seja frequentemente observada em pacientes admitidos no pronto-socorro (PS), não há consenso quanto ao seu manejo. Objetivos: Este estudo teve como objetivo caracterizar os pacientes admitidos no PS com elevação da troponina não-isquêmica e identificar potenciais preditores de mortalidade nessa população. Métodos: Este estudo observacional retrospectivo incluiu pacientes do PS com resultado positivo no teste da troponina entre junho e julho de 2015. Pacientes com diagnóstico clínico de síndrome coronariana aguda [...] Resumo Fundamento: Embora a elevação não isquêmica da troponina seja frequentemente observada em pacientes admitidos no pronto-socorro (PS), não há consenso quanto ao seu manejo. Objetivos: Este estudo teve como objetivo caracterizar os pacientes admitidos no PS com elevação da troponina não-isquêmica e identificar potenciais preditores de mortalidade nessa população. Métodos: Este estudo observacional retrospectivo incluiu pacientes do PS com resultado positivo no teste da troponina entre junho e julho de 2015. Pacientes com diagnóstico clínico de síndrome coronariana aguda
- Open Access
- 1 February 2021
- Published by Elsevier in Revista Portuguesa de Cardiologia
- Vol. 40 (2) , 143-144
Late challenges after full plastic jacket in spontaneous coronary dissection
- 1 February 2021
- Published by Elsevier in Revista Portuguesa de Cardiologia
- Vol. 40 (2) , 143-144
Open AccessLate challenges after full plastic jacket in spontaneous coronary dissection